Outsourcing Pharmaceutical Infrastructure Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing Pharmaceutical Infrastructure Operations
Key considerations for outsourcing energy services.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 56-58

Leveraging combined heat and power


Figure 1: Comparison of separate heat and power generation with cogeneration. (FIGURE IS COURTESY OF THE AUTHORS)
Another key advantage of outsourcing energy management is that full-service outside providers possess the expertise to evaluate, design, build, and then operate technologies such as combined heat and power (CHP) to optimize energy efficiency. CHP, sometimes referred to as cogeneration, is an efficient energy technology that simultaneously generates power (i.e., electricity) and thermal energy, which is used for heating, cooling, and production of high-pressure process steam, while typically consuming only 60% of the fuel required for separate processes (1). Figure 1 illustrates the higher energy efficiency of CHP compared to separate heat and power production. CHP technology is currently experiencing a resurgence in pharmaceutical facilities due to its many operational benefits. CHP can provide increased energy reliability, greater fuel flexibility, and market responsiveness. CHP can also mitigate lost products and research projects due to utility grid failures. CHP reduces greenhouse gas emissions; the waste heat generated during the power production process can be captured, recycled, and used for process applications without the need for boilers within each building.

CHP is a proven solution for industrial manufacturing environments, in which reliable power is crucial. According to the US Environmental Protection Agency's (EPA) Combined Heat and Power Partnership, 88% of existing CHP plants are utilized for industrial purposes (2). The other 12% are used by commercial and institutional entities such as hospitals, municipal and state governments, colleges, and universities. With a full-service outsourcing provider, designing, building, and operating complex energy infrastructure may be achieved seamlessly.

Customers that implement CHP typically experience the following benefits:
  • Cost savings. Burning less fuel generates cost savings. CHP users avoid buying from the market at peak price periods. CHP can also be configured to use locally-sourced renewable fuels.
  • Reliability. Utility power outages will not interrupt CHP operations, so critical processes continue uninterrupted.
  • Environmental benefits. Greenhouse gas emissions and criteria air pollutants are reduced when less fuel is combusted.
  • Fuel diversity. CHP plants may be designed for input of multiple sources of fuel. This multi-fuel ability increases energy security and can also mitigate volatility in fuel commodity prices.

Conclusion

Outsourcing may seem like a simple concept, but the potential benefits are significant, especially when complex energy infrastructure must be operated and maintained at the highest levels of reliability. Pharmaceutical research and manufacturing processes are costly to operate, so outsourcing the facility's energy plant operations and management can be a solution to control costs, reduce fuel and energy consumption, and evaluate and implement energy solutions and technologies that can ensure the integrity of the underlying processes.

Mel Palmer is business development director for Veolia Energy North America,
, tel. 617.849.6656. David Lyons is client operations manager at Dalkia Ireland's Pharmaceutical & Healthcare division.

References

1. EPA, "Efficiency Benefits," http://www.epa.gov/chp/basic/efficiency.html, accessed June 20, 2012.

2. EPA, "Combined Heat and Power FAQ," http://www.epa.gov/chp/documents/faq.pdf, accessed June 22, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here